ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: It has therefore been hypothesized that imatinib inhibition of BCR::ABL1 downregulates PI3K/Akt-signaling, which may, in turn, reduce plasma membrane BCRP activity in CML cells, resulting in less resistance to imatinib [91].